A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
To find out about the safety and good and bad effects of CPI-613 in metastatic pancreatic cancer when used in combination with FOLFIRINOX (FFX).
Metastatic Pancreatic Cancer
- Metastatic adenocarcinoma of the pancreas
- 18-75 years of age
- Prior treatment with any chemotherapy for metastatic adenocarcinoma of the pancreas
18 - 75
Healthy Volunteers Needed
Duration of Participation
At least 6 months of treatment and up to 3 years follow-up.
Knight Clinical Trials Information Line